As far as M&A deals go, 2019 has started off with a boom.
Pfizer to combine off-patent drug business with Mylan
Pfizer has agreed to merge its off-patent drugs business with generic drugmaker Mylan.
Merck will invest some $680M in new manufacturing space and expanded packaging space to support its HPV vaccine Gardisil.
One of the buzziest new drugs has been Pfizer and Eli Lilly’s tanezumab, which works by selectively targeting, binding to and blocking nerve growth factor.
Vertex announced that its chief medical officernwill take over as president and chief executive